BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22445908)

  • 1. Pancreatic cancer stem cells: emerging target for designing novel therapy.
    Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
    Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer stem cells and EMT in drug resistance and metastasis.
    Sarkar FH; Li Y; Wang Z; Kong D
    Minerva Chir; 2009 Oct; 64(5):489-500. PubMed ID: 19859039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
    Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
    Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
    PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of pancreatic cancer stem cell characteristics by α-Mangostin: Molecular mechanisms involving Sonic hedgehog and Nanog.
    Ma Y; Yu W; Shrivastava A; Srivastava RK; Shankar S
    J Cell Mol Med; 2019 Apr; 23(4):2719-2730. PubMed ID: 30712329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
    Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting pancreatic cancer stem cells for cancer therapy.
    Xia J; Chen C; Chen Z; Miele L; Sarkar FH; Wang Z
    Biochim Biophys Acta; 2012 Dec; 1826(2):385-99. PubMed ID: 22728049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway.
    Ma Y; Yu W; Shrivastava A; Alemi F; Lankachandra K; Srivastava RK; Shankar S
    Carcinogenesis; 2017 Oct; 38(10):1047-1056. PubMed ID: 28968696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer stem cells: new insight into a stubborn disease.
    Zhan HX; Xu JW; Wu D; Zhang TP; Hu SY
    Cancer Lett; 2015 Feb; 357(2):429-37. PubMed ID: 25499079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.
    Wang Z; Li Y; Ahmad A; Azmi AS; Kong D; Banerjee S; Sarkar FH
    Drug Resist Updat; 2010; 13(4-5):109-18. PubMed ID: 20692200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.
    Tanase CP; Neagu AI; Necula LG; Mambet C; Enciu AM; Calenic B; Cruceru ML; Albulescu R
    World J Gastroenterol; 2014 Aug; 20(31):10790-801. PubMed ID: 25152582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
    Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
    Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy.
    Wang Z; Ahmad A; Li Y; Azmi AS; Miele L; Sarkar FH
    Anticancer Res; 2011 Apr; 31(4):1105-13. PubMed ID: 21508353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
    Garg M
    Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
    Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
    Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer stem cell in the progression and therapy of pancreatic cancer.
    Xu L
    Front Biosci (Landmark Ed); 2013 Jun; 18(3):795-802. PubMed ID: 23747847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.